Compare iShares MSCI Canada (TSX) (EWC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs McKesson Corporation — how do they compare? iShares MSCI Canada (TSX) trades at $59.03 (market cap $6.99B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 15.5× iShares MSCI Canada (TSX)'s market cap, and McKesson Corporation pays a 0.4% dividend while iShares MSCI Canada (TSX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 56 Days and McKesson Corporation for 74 Days on average.
| EWC | MCK | |
|---|---|---|
Market Cap | $6.99B | $108.46B |
Volume | 1,625,847 | 712,607 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $995.69 |
52-Week Low | $49.72 | $725.17 |
Typical Hold Time | 56 Days | 74 Days |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $58.32, up 0.66% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $59 and support at $58. Recent news highlights trade tensions with the U.S. and Canada's pursuit of EU associate membership, creating uncertainty for the Canadian-focused ETF.
The outlook is cautious due to geopolitical risks and mixed economic data from Canada. While diversification benefits exist, investors face volatility from trade policy shifts. Key risks include U.S. tariff threats and softening manufacturing growth, warranting close monitoring of trade developments.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
